Intellectual Property and Recognition - In 2023, Shanxi Dayu Bioengineering obtained two invention patents: one for glucose oxidase and its preparation method, and another for a high-density culture method of Pichia pastoris[5]. - The company was recognized as a "2023 Typical Case of IoT Empowering Industry Development" by the Ministry of Industry and Information Technology in August 2023[6]. - In November 2023, the company was awarded the title of "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration[7]. - Shanxi Dayu Bioengineering was recognized as a "Demonstration Enterprise of Technological Innovation" by the Shanxi Provincial Department of Industry and Information Technology in October 2023[9]. - The company was awarded the title of "Specialized, Refined, and New Small and Medium-sized Enterprise" by the Shanxi Provincial Small Enterprise Development Promotion Bureau in July 2023[8]. - The total number of patents owned by the company increased to 33 from 31 in the previous period, with invention patents rising to 14 from 12[84]. - The company has been recognized as a high-tech enterprise, benefiting from a reduced corporate income tax rate of 15% for three years[77]. - The company has not reported any significant defects in its internal management systems during the reporting period[166]. Financial Performance - The company's operating revenue for 2023 was approximately ¥160.58 million, representing a year-over-year increase of 2.29% compared to ¥156.98 million in 2022[30]. - The net profit attributable to shareholders of the listed company was approximately -¥2.09 million, a significant decline of 111.52% from ¥18.15 million in 2022[30]. - The gross profit margin decreased to 27.28% in 2023 from 43.80% in 2022[30]. - Total assets at the end of 2023 were approximately ¥423.71 million, down 2.22% from ¥433.32 million at the end of 2022[32]. - Total liabilities increased by 41.61% to approximately ¥106.40 million in 2023 from ¥75.14 million in 2022[32]. - The weighted average return on equity (ROE) based on net profit was -0.62% in 2023, down from 6.07% in 2022[30]. - The net cash flow from operating activities decreased by 71.12% to approximately ¥7.68 million in 2023 from ¥26.60 million in 2022[33]. - The company reported a basic earnings per share of -¥0.02 in 2023, a decline of 105.41% from ¥0.37 in 2022[30]. - The company achieved revenue of 160.58 million yuan, a year-on-year increase of 2.29%, while net profit attributable to shareholders was -2.09 million yuan, a decline of 111.52%[45]. - Total assets amounted to 423.71 million yuan, a decrease of 2.22% compared to the end of the previous year, while total liabilities increased by 41.61% to 106.40 million yuan[45]. - The company reported a significant decrease in cash and cash equivalents by 56.11% to 198.01 million yuan due to the cash dividend payout[51]. - The company reported a significant increase in financial expenses, rising by 617.33% to ¥1,982,084.82, attributed to higher short-term borrowing costs[55][59]. - The company’s main business income rose by 2.52% to ¥157,300,103.00, while other business income decreased by 7.58% to ¥3,276,590.07[61]. Shareholder and Capital Structure - The company distributed a total cash dividend of RMB 38,780,280.00, with a stock increase of 10 shares for every 10 shares held, raising the total share capital to 111,360,400 shares[9]. - The total share capital after the dividend distribution increased to 111,360,400 shares, reflecting a significant increase in shareholder value[9]. - The actual controllers of the company hold a combined 49.94% of shares, which may influence major decisions and potentially affect minority shareholders' interests[107]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[128]. - The company has a total of 55,400,400 shares eligible for dividend distribution based on the equity registration date[142]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 2.4959 million[154]. Research and Development - The company’s research and development expenses were ¥10,260,570.09, accounting for 6.39% of total revenue, showing a slight decrease of 2.10% from the previous year[55]. - The company is developing a high-temperature glucose oxidase with a stability of over 90% enzyme activity at 70°C, which is expected to enhance product functionality and reduce costs[85]. - A new fermentation enzyme with an activity level exceeding 2300 U/ml has been achieved, aimed at improving product functionality and generating economic benefits[85]. - The company has completed research on a probiotic strain that shows a 95.1% inhibition rate against E. coli and a 91.0% inhibition rate against Staphylococcus aureus, indicating potential for new product development[86]. - The company is exploring the use of plant essential oils as a substitute for antibiotics in animal feed, focusing on the synergistic effects of oregano oil[87]. - The company has optimized the fermentation process for a selected strain of Bacillus, DY9000, which is anticipated to lower production costs[24]. - The company is committed to environmental protection, ensuring compliance with national regulations and effectively controlling waste emissions[97]. Market and Industry Trends - The company aims to expand its market share in feed additives and veterinary medicine, focusing on product quality and cost reduction[41]. - The average price of live pigs for the year was 15.03 yuan/kg, leading to continuous losses for farmers due to oversupply and weak consumption[48]. - The total output value of the national feed industry reached 1,401.83 billion yuan, a year-on-year growth of 6.5%[48]. - The company focused on promoting feed products, achieving a certain growth despite a decline in mixed feed additive sales[45]. - The industry trend emphasizes precision nutrition, which is expected to drive the feed and feed additive sector towards more refined practices[100]. Governance and Compliance - The company has established a comprehensive audit process to ensure the accuracy of financial reporting and compliance with auditing standards[93]. - The company has implemented strict confidentiality procedures for undisclosed insider information to protect investor interests[174]. - The company has maintained a stable governance structure, ensuring that all meetings and decisions comply with legal requirements[171]. - The audit committee of the board confirmed that the financial reports accurately reflect the company's performance and financial status[175]. - The company has engaged a reputable auditing firm to conduct its annual financial audit, ensuring independence and capability[175]. Employee and Management Changes - The total number of employees decreased from 433 to 382, a reduction of approximately 11.8%[156]. - The number of production personnel decreased from 167 to 143, a reduction of 14.4%[155]. - The company emphasizes employee training and development, implementing various training programs for new and existing employees[157]. - New General Manager Yan Lingpeng was appointed in April 2023, succeeding Yan Heping who resigned from the position for personal reasons[151]. - The company has a father-son relationship between Chairman Yan Heping and General Manager Yan Lingpeng[147]. Strategic Goals and Future Plans - The company plans to diversify its product line and reduce reliance on single products to mitigate market risks[105]. - The company aims to develop local feed structures that utilize regional by-products, promoting local economic development[24]. - The company plans to enhance its research and development capabilities through partnerships with industry experts to maintain competitiveness and meet market demands[107]. - The 2024 strategic goals include focusing on key products and increasing customer development efforts to drive sustainable growth[102].
大禹生物(871970) - 2023 Q4 - 年度财报